The Impact of Brief Behavioral Treatment for Insomnia Versus Brief Mindfulness Treatment on Cognition and Sleep Health in Adults (Age 50+) With HIV

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age50-99
SponsorUniversity of Alabama, Tuscaloosa

About this trial

The goal of this clinical trial is to examine the effects of a telephone-delivered Brief Behavioral Treatment Insomnia (BBTI) versus a Brief Mindfulness Treatment (BMT) on cognitive and sleep outcomes in older adults with HIV. The main questions it aims to answer are:

What are the effects of BBTI vs BMT on self-reported and observed sleep outcomes in older adults with HIV and insomnia up to 1-year post-intervention? What are the effects of BBTI vs BMT on self-reported and observed cognitive comes in older adults with HIV and insomnia up to 1-year post-intervention? What is the association between Alzheimer's Disease biomarkers and sleep and cognitive outcomes in older adults with HIV receiving BBTI vs BMT?

Participants will:

* Complete 4 weeks of telephone-delivered BBTI or BMT * Attend baseline, post-intervention, and 1-year post in-person visits for sleep and cognitive assessments * Have blood collected at all three time points

Eligibility criteria

Qualifiers

must be age 50 or older

have a DSM-5 diagnostic criteria for insomnia including sleep difficulty that occurs at least 3 times per week and has been a problem for at least 3 consecutive months (indicated on the Structured Clinical Interview for Sleep Disorders, SCISD) during telephone screening

have a confirmed HIV diagnosis and a prescribed ART regimen for at least 12 months.

Disqualifiers

unable to speak English

have a reported or documented (in medical records) diagnosis of AD or dementia

have severe neurocognitive impairment (>7 errors on the Short Portable Mental Status Questionnaire, SPMSQ) during telephone screening

have a history of a stroke

Trial design

Treatments tested in this trial

  • BBTI
  • BMT

Treatment groups

214 Participants
are divided into 2 treatment groups

Sponsors and collaborators

University of Alabama, Tuscaloosa

Lead sponsor

University of Alabama at Birmingham

Collaborator

National Institute on Aging (NIA)

Collaborator

NIH Office of AIDS Research (OAR)

Collaborator